DelveInsight’s Trending Reports 2022: Ehlers-Danlos Syndrome Market, X Linked Hypophosphatemia Market, Thyroid Eye Disease Market, Primoridal Dwarfism Market, Sialidosis Market.

Ehlers-Danlos Syndrome Market

Ehlers-Danlos syndrome

Some facts of Ehlers-Danlos Syndrome Market Report are:

at least 1 in 5,000 individuals worldwide.

· Vascular EDS is reported to have a prevalence of 1 in 100,000 individuals, and cardiac-valvular EDS a prevalence of less than 1 in a million people.

· The estimated prevalence for all EDS varies between 1/10,000 and 1/25,000, EDS type IV representing approximately 5 to 10% of cases.

View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market

Some of Ehlers-Danlos Syndrome Companies are:

· Aventis Pharmaceuticals

· EVAMED

· Acer Pharma

· And Many Others

View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market

Ehlers-Danlos Syndrome Therapies are:

· Celiprolol

· Irbesartan

· And Many Others


X Linked Hypophosphatemia Market

X-linked hypophosphatemia

Some facts of X Linked Hypophosphatemia Market Report are:

· According to study conducted by He ́le`ne et al., titled “Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms”, the estimated prevalence of X-linked hypophosphatemia was 4.8 per 100,000.

· As per Endocrine Society, the Food and Drug Administration (FDA) estimates that XLH affects about 3,000 children and 12,000 adults in the United States

· According to Phosphodiabetes E.V. Netzwerk Information Austausch, estimates that X-linked hypophosphatemia (XLH) is the most common form of vitamin D-resistant rickets and, with a prevalence of 4.8 cases per 100,000 individuals, is considered a rare disease.

· The study by Riancho et al., titled “Osteomalacia and rickets” estimates that the prevalence of Hypophosphatemic rickets linked to the X chromosome due to a mutation in the PHEX gene is around 5 per 100,000.

View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market

Some of X Linked Hypophosphatemia Companies are:

· Ultragenyx

· Validus Pharmaceuticals

· Prospec-Tany Technogene Ltd

· Merck KGaA

· Zeria Pharmaceutical Co., Ltd

· Smith & Nephew

· Narang Medical Limited

· Eli Lilly and Company

· F. Hoffmann-La Roche Ltd

· And Many Others

View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market

X Linked Hypophosphatemia Therapies are:

· Burosumab

· Crysvita

· And Many Others


Thyroid Eye Disease Market

Thyroid eye disease (TED

Thyroid eye disease Facts

· In a study by Zagaria et al. [2011], it was observed that approximately 25‐30% of patients with Graves’ disease have clinical evidence of Graves’ ophthalmopathy.

· As per the study by Liaboe et al., titled “An Introductory Tutorial and Overview of Disease”, TED has a higher prevalence in women than men (16 per 100,000 vs. 3 per 100,000, respectively). Both men and women demonstrate a bimodal pattern of age of diagnosis(40–44 and 60–64 yearsin women; 45–49 and 65–69 years in men).

· The study by Lazarus et al. titled “Epidemiology of Graves’ orbitopathy (GO and relationship with thyroid disease” estimates that Graves’ ophthalmopathy (GO) occurs mainly, but not exclusively, in patients with Graves’ disease. However, only about <50% of Graves’ patients have clinically apparent ophthalmopathy, where the approximate prevalence is 0.25%.

· According to a review article titled “Epidemiology and Prevention of Graves’ Ophthalmopathy” by Wilmar et al., Graves’ ophthalmopathy is clinically relevant in approximately 50% of patients with Graves' disease, and severe forms affects less than 5% of patients.

View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market

Some of Thyroid eye disease Companies

· Immunovant Sciences

· Horizon Therapeutics

· And Many Others

Thyroid eye disease Drugs Covered:

· IMVT‐1401

· Teprotumumab

· And Many Others

View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market


Primoridal Dwarfism Market

Primordial dwarfism

Some facts of Primordial Dwarfism Market Report

· Primordial Dwarfism Market size is expected to change for 7MM during the forecast period of 2018-30.

· Its prevalence report estimates 4 million babies to die in the first 4 weeks of life (the neonatal period) with almost 99 % of neonatal deaths (Lawn et al. 2011; Cous-ens et al. 1995).

· The modern prevalence of MOPDII is unknown, but between 150 and 200 cases are reported worldwide each year (Bober and Jackson, 2017).

· All types of primordial dwarfism are caused by changes in genes. Different gene mutations cause the different conditions that make up primordial dwarfism.

· Primordial dwarfism can be difficult to diagnose. This is because the small size and low body weight could be a sign of other things, such as poor nutrition or a metabolic disorder.

To get more detailed insight on Primordial Dwarfism Market Report@Request for a Sample Report here: https://www.delveinsight.com/report-store/primordial-dwarfism-market

Some of Primordial Dwarfism Companies are:

· GeneScience Pharmaceuticals

· Merck

· Genentech, Inc.

· Pfizer

· Novo Nordisk

· EMD Serono

· And Many Others

Primordial Dwarfism Therapies are:

· Jintrolong® low dose group

· Recombinant human growth hormone (r-hGH)

· Somatropin

· And Many Others

To get more detailed insight about Primordial Dwarfism Therapies@Request for a Sample Report here: https://www.delveinsight.com/report-store/primordial-dwarfism-market


Sialidosis Market

Sialidosis

Some of Sialidosis facts

· As per ISMRD, Sialidosis is among the rarest Lysosomal Storage Diseases, affecting perhaps less than 1:4,000,000 worldwide and is thought to be more common in people with Italian ancestry.

· As per the International Advocate for Glycoprotein Storage Diseases (ISMRD), Type I is the mildest form of Sialidosis, with a range of onset from anywhere between 8-25 years of age.

· According to NORD, Sialidosis affects males and females in equal number.

· The prevalence is estimated to be less than 1/1,000,000.

https://www.delveinsight.com/report-store/sialidosis-market

Get in touch with our Business executive for Rich and Deep Healthcare Consulting Solutions

Competitive Intelligence Service

Some of Newly Launched Report:

Acute Lung Injury Market

Adamantinoma Market

Defibrillators Market

Urolithiasis Market

Cardiac Resynchronization Therapy Device Market

Aesthetic Implants Market

Alzheimer Disease Market

Central Venous Catheters Market

Biochips Market

Alopecia Market

Cardiac Monitoring Devices Market

Biliary Tumor Market

Foot And Ankle Devices Market

Hyperuricemia Market

Invasive Candidiasis Market

Global Electrophysiology Devices Market

Neurovascular Devices Market

Blood Glucose Monitoring Systems Market

Neurostimulation Devices Market

Human Papilomavirus Market

Capnography Device Market

Ventilator Market

Breast Pumps Market

Metastatic Bone Pain Market

Brain Aneurysm Stents Market

Atypical Hemolytic Uremic Syndrome Ahus Market

2 Deletion Syndrome Market

X Linked Hypophosphatemia Market

Parkinsons Disease Related Dementia Market

Ocular Motility Disturbance Market

Palmar Hyperhidrosis Market Size

Pulse Oximeters Market

Diagnostic Imaging Equipment Market

Continuous Renal Replacement Therapy Machines Market

Pain Management Devices Market

Glycogen Storage Disease Market

Rituximab Biosimilars Insight

Epithelial Ovarian Cancer Market

Cardiac Biomarkers Testing Devices Market

Chronic Myelogenous Leukemia Market

Bone Grafts And Substitutes Market

Idiopathic Membranous Nephropathy Market

Advanced Renal Cell Carcinoma Market

Sialidosis Market

Prosthetic Joint Infection Market

Microsatellite Stable Colorectal Cancer Market

Higher-Risk Chronic Myelomonocytic Leukemia Market

Chondrosarcoma Market

Car T Therapy For Acute Lymphoblastic Leukemia All Market


Related Blogs:

Artificial Intelligence (AI) in Healthcare Segment

Biggest Pharmaceutical Companies by Continents

HPV Vaccine Reduces Cervical Cancers and Precancers

Major Drugs Decisions for Cardiovascular Diseases to Watch Through 2022

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Evaluation of Rapidly Evolving Parkinson’s Disease Therapeutic Market

Cybersecurity in Healthcare: Major Threats and Challenges

Top Drugs To Watch in HIV (2025)


About Delveinsight:

Market Research

PharmDelve

Media Contact

Company Name:

Contact Person:

Email:

Phone:+19193216187

City:

State:

Country:

Website:https://www.delveinsight.com

Connect With Us at:

LinkedIn Facebook Twitter

Follow
4.7 Star App Store Review!
Cpl.dev***uke
The Communities are great you rarely see anyone get in to an argument :)
king***ing
Love Love LOVE
Download

Select Collections